Kapstone Financial Advisors LLC Purchases Shares of 465 Eli Lilly and Company (NYSE:LLY)

Kapstone Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 465 shares of the company’s stock, valued at approximately $292,000.

Other hedge funds have also added to or reduced their stakes in the company. Lipe & Dalton acquired a new position in Eli Lilly and Company during the 4th quarter valued at about $26,000. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company during the 3rd quarter valued at about $27,000. Legacy Financial Group LLC acquired a new position in Eli Lilly and Company during the 3rd quarter valued at about $35,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company during the 3rd quarter valued at about $36,000. Finally, Family CFO Inc acquired a new position in Eli Lilly and Company during the 3rd quarter valued at about $40,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY stock traded up $8.64 during midday trading on Friday, reaching $733.51. 2,009,249 shares of the company’s stock traded hands, compared to its average volume of 2,265,427. The company has a 50-day moving average price of $761.79 and a two-hundred day moving average price of $666.67. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a 52 week low of $380.77 and a 52 week high of $800.78. The firm has a market capitalization of $696.95 billion, a PE ratio of 126.47, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the previous year, the firm posted $2.09 EPS. The business’s revenue for the quarter was up 28.1% compared to the same quarter last year. As a group, equities analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on LLY. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. BMO Capital Markets boosted their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Monday, April 15th. Finally, Citigroup boosted their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.